Arketamine for bipolar depression: Open-label, dose-escalation, pilot study.

[1]  G. Sanacora,et al.  Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study. , 2023, Journal of affective disorders.

[2]  Z. Cordner,et al.  Bipolar depression: a review of treatment options , 2022, General Psychiatry.

[3]  S. Wilkinson,et al.  Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting. , 2022, JAMA psychiatry.

[4]  P. Cowen,et al.  Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. , 2021, The Cochrane database of systematic reviews.

[5]  L. Quarantini,et al.  Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial. , 2021, Journal of psychiatric research.

[6]  C. Zarate,et al.  Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. , 2020, Journal of affective disorders.

[7]  A. Carvalho,et al.  Bipolar Disorder. , 2020, The New England journal of medicine.

[8]  L. Quarantini,et al.  NMDA Antagonists and Their Role in the Management of Bipolar Disorder: a Review , 2020, Current Behavioral Neuroscience Reports.

[9]  C. Loo,et al.  Intravenous arketamine for treatment-resistant depression: open-label pilot study , 2020, European Archives of Psychiatry and Clinical Neuroscience.

[10]  C. Loo,et al.  Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. , 2019, Journal of affective disorders.

[11]  J. Calabrese,et al.  Bipolar depression: the clinical characteristics and unmet needs of a complex disorder , 2019, Current medical research and opinion.

[12]  K. Hashimoto.  Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective , 2019, Psychiatry and clinical neurosciences.

[13]  Chang Liu,et al.  Abnormal resting-state cerebral-limbic functional connectivity in bipolar depression and unipolar depression , 2019, BMC Neuroscience.

[14]  Lisa M. DeBruine,et al.  Understanding Mixed-Effects Models Through Data Simulation , 2019, Advances in Methods and Practices in Psychological Science.

[15]  Kyu-Man Han,et al.  Differentiating between bipolar and unipolar depression in functional and structural MRI studies , 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[16]  G. Turecki,et al.  Comparative study of esketamine and racemic ketamine in treatment-resistant depression , 2018, Medicine.

[17]  D. M. Lyons,et al.  Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. , 2018, The American journal of psychiatry.

[18]  A. Nierenberg,et al.  Functional Connectivity Between Anterior Insula and Key Nodes of Frontoparietal Executive Control and Salience Networks Distinguish Bipolar Depression From Unipolar Depression and Healthy Control Subjects. , 2018, Biological psychiatry. Cognitive neuroscience and neuroimaging.

[19]  K. Hashimoto,et al.  Mechanistic Target of Rapamycin–Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model , 2018, Biological Psychiatry.

[20]  Per B. Brockhoff,et al.  lmerTest Package: Tests in Linear Mixed Effects Models , 2017 .

[21]  J. Mann,et al.  Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam‐controlled randomized clinical trial , 2017, Bipolar disorders.

[22]  K. Hashimoto,et al.  R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects , 2015, Translational Psychiatry.

[23]  David A. Magezi,et al.  Linear mixed-effects models for within-participant psychology experiments: an introductory tutorial and free, graphical user interface (LMMgui) , 2015, Front. Psychol..

[24]  K. Hashimoto,et al.  R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine , 2014, Pharmacology Biochemistry and Behavior.

[25]  D. Luckenbaugh,et al.  Subanesthetic Dose Ketamine Does Not Induce an Affective Switch in Three Independent Samples of Treatment-Resistant Major Depression , 2013, Biological Psychiatry.

[26]  D. Luckenbaugh,et al.  Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial , 2012, Biological Psychiatry.

[27]  R. Kessler,et al.  Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. , 2011, Archives of general psychiatry.

[28]  E. Domino.  Taming the Ketamine Tiger , 2010, Anesthesiology.

[29]  D. Luckenbaugh,et al.  A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. , 2010, Archives of general psychiatry.

[30]  M. Durieux,et al.  Ketamine: Teaching an Old Drug New Tricks , 1998, Anesthesia and analgesia.